TRIPLE INCRETIN / GLUCAGON AGONIST
1 vial · lyophilized · ≥99% purity target
Research use only
Retatrutide is a synthetic peptide engineered as a single-molecule agonist at three receptors: GLP-1, GIP and glucagon. In published work it is treated as a metabolic-hormone analogue for laboratory and clinical-research study of energy balance and glycemic signaling. It is not presented here as a licensed medicine.
The literature places retatrutide in metabolic research: body-weight biology, energy expenditure and glycemic control in clinical and preclinical papers on triple agonism. These are research territories, not outcomes a visitor should expect. Published papers examine retatrutide as a simultaneous GLP-1, GIP and glucagon receptor agonist. This page documents the material on file. It does not instruct use.
Analysis performed by an independent laboratory. Document reproduced as received.